The MNT Transcription Factor Autoregulates Its Expression And

Total Page:16

File Type:pdf, Size:1020Kb

Load more

Downloaded from http://www.jbc.org/ at Centro Nacional de Investigaciones Cardiovasculares (CNIC) on July 8, 2020 cro 2001 promoter, an , ‡ MNT , ¶ , and ‡ ). MYC can also interact 1 ), which alternatively can (2020) 295(7) 2001–2017 ). Whereas MYC–MAX, upon 6, 7 , Rosa Blanco ) serving as the link between ‡ 2, 3 8, 9 , Peter Hurlin § J. Biol. Chem. MLX–MONDO. protein MLX ( , M. Dolores Delgado § , Ignacio Varela MLXIP (MONDOA) and MLXIPL (MONDOB) ‡4 and bind E-boxes ( E-boxes, acts primarily as a transcriptional activator, is a basic helix-loop-helix leucine zipper (bHLH-LZ) ). MNT can bind not only to MAX but also to the Division of Basic Sciences, Fred Hutchinson Cancer , Patrick Carroll 10 § ‡ 4, 5 MNT is expressed constitutively in proliferating and quies- MNT bHLH-LZ, basic helix-loop-helix leucine zipper;tor MAX, X; MYC-associated fac- qPCR, quantitativeGSEA, PCR; Gene RNA-seq, Set RNA Enrichment sequencing;reads FL, Analysis; per kilobase full-length; ChIP-seq, pair ChIP-sequencing; per million. RPKM, The abbreviations used are: MNT, MAX network transcriptional repressor; binding to interact with proteins. Therefore, MNT participates bothMLX-centered in the networks MAX- ( and protein, and it is the mostily, divergent member which of the also MXDMNT fam- includes forms MXD1, heterodimers MXI1, withdomain MAX MXD3, and binds through to and E-box the DNA MXD4. bHLH-LZ most sequences. prevalent MYC human is oncoproteins one ( of the the typical effect of MNT–MAXsion is ( the transcriptional repres- cent cells, and the protein levels do not show major fluctuations with MAX MAX–MYC and 10 MAX-like HLH MNT–MAX dimers bind andeffect repress that depends the on one of theIn two MAX-deficient E-boxes cells, on MNT this was promoter. overexpresseduted and to redistrib- the cytoplasm. Interestingly, MNTproliferation was required even for cell in theMAX-deficient absence cells, of MNT MAX.homodimers. RNA-sequencing We experiments binds revealed that show MNT to thatregulates the in MLX, expression of but several genesMAX, even with also in many the of forms these absence genes of beingulation and involved DNA in repair. cell Of cycle note, reg- MNT–MNT homodimersulated reg- the transcription of some genesation. involved The in cell tight prolifer- regulationwithout of MAX suggest MNT a major and role for its MNT in functionality cell proliferation. even . Published, Papers in Press, January 9, 2020, DOI 10.1074/jbc.RA119.010389 , Ester Molina , Robert N. Eisenman ‡7 8 ʈ , Andrea Quintanilla ‡1,3 Shriners Hospitals for Children Research Center, and Department of Cell, ¶ [email protected] oncogene modula- , Julia Aresti ‡6 . MYC , Judit Liaño-Pons ‡1,2 , Montse Sanchez-Céspedes ʈ , Gabriel Bretones ‡5 Figs. S1–S9 and Tables S1–S8 ‡9 Instituto de Biomedicina y Biotecnología de Cantabria (IBBTEC), Universidad de Cantabria-CSIC, and Department of ‡ ARTICLE Genes and Cancer Group, Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute–IDIBELL, ʈ Javier León Octavio A. Romero tute, University of Groningen, 9712 CP Groningen, Netherlands. Germans Trias i Pujol, 08916 Badalona, Barcelona, Spain. Medicina, Instituto UniversitarioOviedo, de 33003 Oncología Oviedo, Asturias, (IUOPA), Spain. Universidad de ics and Molecular Medicine,United University Kingdom. of Edinburgh, EH4 2XU Scotland, Catarina (UFSC), 88040-900 Florianópolis, Brazil. address: Sorrell Lab, Dept. ofter, Cell Dallas, Biology, TX UT 75390. Southwestern Medical Cen- Investigación, Spanish Government (to J. L. andFEDER M. D. Program D.), funded from in part the by Grant CA57138/CA European from NCI Union, (to R. National N.for E.), Institutes and Children grants of from (to Shriners P. Health Hospitals J. H.).interest The with authors the declare contents that of theysibility this have of article. no the The conflicts authors content and of is doesof solely not the necessarily the National represent respon- Institutes the of official Health. views Archive with the accession number PRJEB23604. The MAX network transcriptional repressor (MNT) is an To whom correspondence should be addressed. E-mail: Present address: Groningen Biomolecular Sciences and Biotechnology Insti- Present address: Josep Carreras Leukemia Research Institute, Campus ICO- Present address: Dept. de Bioquímica y Biología Molecular, Facultad de Recipient of an F.P.U. fellowship fromPresent the address: Spanish Edinburgh Government. Cancer Research UK Centre, Institute of Genet- Present address: Dept. of Biochemistry, Universidade Federal de Santa Both authors contributed equally to thisRecipient work. of an F.P.U. fellowship from the Spanish Government. Present Developmental and Cancer Biology, Knight Cancer Institute,the Oregon Health and Science University, Portland, Oregon 97239, and Research Center, Seattle, Washington 98109, the X 7 8 9 6 4 5 1 2 3 This work was supported by Grant SAF2017-88026-R from Agencia Estatal de The RNA-seq and ChIP-seq data have been deposited to the European Nucleotide This article contains Edited by Eric R. Fearon From the (MAX)-deficient cells M. Carmen Lafita-Navarro Fabiana Ourique and supports proliferation in MYC-associated factor X Received for publication, July 28, 2019, and in revised form, December 16, 2019 The MNT transcription factor autoregulates its expression X tor, but little is knownMNT about localizes its to regulation. the We nucleus show of here MAX-expressing cells that and that MXD family transcription factor(bHLH) of family. the basic MNT helix-loop-helix dimerizesregulator, MYC-associated factor with X (MAX), another and down-regulates transcriptional genes by binding to E-boxes. MAX alsooncogenic dimerizes bHLH with transcription MYC, factor. an Upon E-boxMYC–MAX binding, dimer the activates gene expression. MNT also bindsthe to MAX dimerization proteinand MLX MNT–MAX (MLX), dimers and co-exist. However, MNT–MLX have all been attributed MNT to functions MNT–MAX dimers, and nothe functions of MNT–MLX dimer have beenrole has described. been linked MNT’s to biological its function as a 08908 Barcelona, Spain Molecular Biology, Universidad de Cantabria, 39005 Santander, Spain, the © 2020 Lafita-Navarro et al. Published under exclusive license by The American Society for Biochemistry and Molecular Biology, Inc. MNT functions in the absence of MAX when quiescent cells are mitotically stimulated (5, 10, 11). For this purpose, we transfected UR61 cells with a construct MntϪ/Ϫ mice are not viable (10, 12), whereas Mxd1Ϫ/Ϫ, carrying human MAX cDNA driven by the metallothionein ϩ Mxi1Ϫ/Ϫ, and Mxd3Ϫ/Ϫ mice survive, suggesting that MNT promoter, which is activated by Zn2 cations (24). Several function is not redundant with that of the other MXD proteins clones were isolated, and two of them with robust MAX induc- (13–15). Moreover, MNT is the only MXD-related protein in tion were mixed, and the resulting cells were termed URMax34. invertebrates (9). We also generated a cell line transfected with the empty vector, Consistent with MNT functioning as a MYC transcriptional termed URMT, which is a pool of five transfected clones. The 2ϩ antagonist, enforced MNT expression inhibits cell proliferation induction of MAX in response to Zn in URMax34 cells was and impairs MYC-dependent transformation (5, 11). The defi- confirmed by immunoblot (Fig. 1B). We examined the effect of ciency or down-regulation of MNT in fibroblasts leads to MAX induction on MNT levels in URMax34 cells, and we increased proliferation (i.e. similarly to MYC overexpression) found that MNT was down-regulated upon MAX induction by Zn2ϩ (Fig. 1B). As expected, the treatment of URMT cells with and partially rescues the proliferative arrest caused by MYC Downloaded from 2ϩ deficiency (10, 11, 16, 17). MNT ablation in vivo leads to breast Zn did not change the MNT levels (Fig. S1A). To confirm this and T-cell tumors (10, 12, 17), and according to the Cancer result and rule out effects potentially related to the generation Genome Atlas, about 10% of human tumors show deletion of a of stably transfected clones (as the URMax34 system), UR61 MNT allele (1). cells were transiently transfected with a MAX expression vec- tor, and the results showed a decrease in MNT protein levels in Partial or total MNT deficiency in mouse models impairs http://www.jbc.org/ MAX-transfected cells (Fig. 1C). It is noteworthy that the MYC-dependent tumorigenesis (18, 19), and MNT knockout in down-regulation of MNT provoked by the re-expression of some cell models inhibits proliferation and promotes apoptosis MAX in these cells also occurred at the mRNA levels, as deter- (10, 16, 17). Thus, MYC and MNT proteins co-exist in prolif- mined by RT-qPCR (Fig. 1D). We then analyzed the effect of erating cells, and depending on the model, MNT acts as a MYC MAX-enforced expression in three human small-cell lung can- antagonist or a cooperator of MYC. cer cell lines deficient in MAX (21). MAX-enforced expression at Centro Nacional de Investigaciones Cardiovasculares (CNIC) on July 8, 2020 However, there is scarce information about MNT transcrip- was achieved by lentiviral transduction, and the levels of MNT tional regulation, and it is unknown whether MNT exerts func- were examined by immunoblot in Lu134, Lu165, and H1417 tions without MAX. In this work, we studied possible MAX- cell lines (Fig. 1E). In all cell lines, MAX expression resulted in independent functions of MNT using UR61 cells as the main lower MNT protein levels. The MNT mRNA levels were also model. These rat pheochromocytoma cells do not express down-regulated in Lu165 and in H1417 cells upon MAX a functional MAX protein but a truncated form (termed expression (Fig. 1F). PC12 MAX ) that lacks the second helix and leucine zipper region We next sought to confirm this in a different cell type with of the bHLH-LZ domain, which are the regions responsible for endogenous MAX. A MAX expression vector was transfected dimerization with MYC and MNT (20).
Recommended publications
  • Pluripotency Factors Regulate Definitive Endoderm Specification Through Eomesodermin

    Pluripotency Factors Regulate Definitive Endoderm Specification Through Eomesodermin

    Downloaded from genesdev.cshlp.org on September 23, 2021 - Published by Cold Spring Harbor Laboratory Press Pluripotency factors regulate definitive endoderm specification through eomesodermin Adrian Kee Keong Teo,1,2 Sebastian J. Arnold,3 Matthew W.B. Trotter,1 Stephanie Brown,1 Lay Teng Ang,1 Zhenzhi Chng,1,2 Elizabeth J. Robertson,4 N. Ray Dunn,2,5 and Ludovic Vallier1,5,6 1Laboratory for Regenerative Medicine, University of Cambridge, Cambridge CB2 0SZ, United Kingdom; 2Institute of Medical Biology, A*STAR (Agency for Science, Technology, and Research), Singapore 138648; 3Renal Department, Centre for Clinical Research, University Medical Centre, 79106 Freiburg, Germany; 4Sir William Dunn School of Pathology, University of Oxford, Oxford OX1 3RE, United Kingdom Understanding the molecular mechanisms controlling early cell fate decisions in mammals is a major objective toward the development of robust methods for the differentiation of human pluripotent stem cells into clinically relevant cell types. Here, we used human embryonic stem cells and mouse epiblast stem cells to study specification of definitive endoderm in vitro. Using a combination of whole-genome expression and chromatin immunoprecipitation (ChIP) deep sequencing (ChIP-seq) analyses, we established an hierarchy of transcription factors regulating endoderm specification. Importantly, the pluripotency factors NANOG, OCT4, and SOX2 have an essential function in this network by actively directing differentiation. Indeed, these transcription factors control the expression of EOMESODERMIN (EOMES), which marks the onset of endoderm specification. In turn, EOMES interacts with SMAD2/3 to initiate the transcriptional network governing endoderm formation. Together, these results provide for the first time a comprehensive molecular model connecting the transition from pluripotency to endoderm specification during mammalian development.
  • Variations in Microrna-25 Expression Influence the Severity of Diabetic

    Variations in Microrna-25 Expression Influence the Severity of Diabetic

    BASIC RESEARCH www.jasn.org Variations in MicroRNA-25 Expression Influence the Severity of Diabetic Kidney Disease † † † Yunshuang Liu,* Hongzhi Li,* Jieting Liu,* Pengfei Han, Xuefeng Li, He Bai,* Chunlei Zhang,* Xuelian Sun,* Yanjie Teng,* Yufei Zhang,* Xiaohuan Yuan,* Yanhui Chu,* and Binghai Zhao* *Heilongjiang Key Laboratory of Anti-Fibrosis Biotherapy, Medical Research Center, Heilongjiang, People’s Republic of China; and †Clinical Laboratory of Hong Qi Hospital, Mudanjiang Medical University, Heilongjiang, People’s Republic of China ABSTRACT Diabetic nephropathy is characterized by persistent albuminuria, progressive decline in GFR, and second- ary hypertension. MicroRNAs are dysregulated in diabetic nephropathy, but identification of the specific microRNAs involved remains incomplete. Here, we show that the peripheral blood from patients with diabetes and the kidneys of animals with type 1 or 2 diabetes have low levels of microRNA-25 (miR-25) compared with those of their nondiabetic counterparts. Furthermore, treatment with high glucose decreased the expression of miR-25 in cultured kidney cells. In db/db mice, systemic administration of an miR-25 agomir repressed glomerular fibrosis and reduced high BP. Notably, knockdown of miR-25 in normal mice by systemic administration of an miR-25 antagomir resulted in increased proteinuria, extracellular matrix accumulation, podocyte foot process effacement, and hypertension with renin-angiotensin system activation. However, excessive miR-25 did not cause kidney dysfunction in wild-type mice. RNA sequencing showed the alteration of miR-25 target genes in antagomir-treated mice, including the Ras-related gene CDC42. In vitro,cotrans- fection with the miR-25 antagomir repressed luciferase activity from a reporter construct containing the CDC42 39 untranslated region.
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus

    A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus

    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
  • 1 Supporting Information for a Microrna Network Regulates

    1 Supporting Information for a Microrna Network Regulates

    Supporting Information for A microRNA Network Regulates Expression and Biosynthesis of CFTR and CFTR-ΔF508 Shyam Ramachandrana,b, Philip H. Karpc, Peng Jiangc, Lynda S. Ostedgaardc, Amy E. Walza, John T. Fishere, Shaf Keshavjeeh, Kim A. Lennoxi, Ashley M. Jacobii, Scott D. Rosei, Mark A. Behlkei, Michael J. Welshb,c,d,g, Yi Xingb,c,f, Paul B. McCray Jr.a,b,c Author Affiliations: Department of Pediatricsa, Interdisciplinary Program in Geneticsb, Departments of Internal Medicinec, Molecular Physiology and Biophysicsd, Anatomy and Cell Biologye, Biomedical Engineeringf, Howard Hughes Medical Instituteg, Carver College of Medicine, University of Iowa, Iowa City, IA-52242 Division of Thoracic Surgeryh, Toronto General Hospital, University Health Network, University of Toronto, Toronto, Canada-M5G 2C4 Integrated DNA Technologiesi, Coralville, IA-52241 To whom correspondence should be addressed: Email: [email protected] (M.J.W.); yi- [email protected] (Y.X.); Email: [email protected] (P.B.M.) This PDF file includes: Materials and Methods References Fig. S1. miR-138 regulates SIN3A in a dose-dependent and site-specific manner. Fig. S2. miR-138 regulates endogenous SIN3A protein expression. Fig. S3. miR-138 regulates endogenous CFTR protein expression in Calu-3 cells. Fig. S4. miR-138 regulates endogenous CFTR protein expression in primary human airway epithelia. Fig. S5. miR-138 regulates CFTR expression in HeLa cells. Fig. S6. miR-138 regulates CFTR expression in HEK293T cells. Fig. S7. HeLa cells exhibit CFTR channel activity. Fig. S8. miR-138 improves CFTR processing. Fig. S9. miR-138 improves CFTR-ΔF508 processing. Fig. S10. SIN3A inhibition yields partial rescue of Cl- transport in CF epithelia.
  • Kruppel-Like Factor 9 Inhibits Glioblastoma Stemness

    Kruppel-Like Factor 9 Inhibits Glioblastoma Stemness

    KRUPPEL-LIKE FACTOR 9 INHIBITS GLIOBLASTOMA STEMNESS THROUGH GLOBAL TRANSCRIPTION REPRESSION AND INHIBITION OF INTEGRIN ALPHA 6 AND CD151 By Jessica Tilghman A dissertation submitted to Johns Hopkins University in conformity with the requirements for the degree of Doctor of Philosophy Baltimore, Maryland October, 2015 Abstract Glioblastoma (GBM) stem cells (GSCs) represent tumor-propagating cells with stem-like characteristics (stemness) that contribute disproportionately to GBM drug resistance and tumor recurrence. Understanding the mechanisms supporting GSC stemness is important for developing novel strategies that target tumor propagation to inhibit cancer progression and improve patient survival. Krüppel-like factor 9 (KLF9) has emerged as a regulator of cell differentiation, neural development, and oncogenesis; however, the molecular basis for KLF9’s diverse contextual functions has been unclear. We establish for the first time a genome-wide map of KLF9-regulated targets in human glioblastoma stem-like cells, and show that KLF9 functions as a transcriptional repressor and thereby regulates multiple signaling pathways involved in oncogenesis and regulation of cancer stem-like phenotype. A detailed analysis of two novel KLF9 targets suggests that KLF9 inhibits glioma cell stemness by repressing expression of integrin α6 and CD151. The expression of one candidate KLF9 target gene ITGA6 coding for integrin α6 was verified to be downregulated by KLF9 in GSCs. ITGA6 transcription repression by KLF9 altered GBM neurosphere cell behavior as evidenced by reduced cell adhesion to and migration through membrane coated with the integrin α6 ligand laminin. Forced expression of integrin α6 partially rescued GBM neurosphere cells from the differentiating and adhesion/migration-inhibiting effects of KLF9.
  • Association of Gene Ontology Categories with Decay Rate for Hepg2 Experiments These Tables Show Details for All Gene Ontology Categories

    Association of Gene Ontology Categories with Decay Rate for Hepg2 Experiments These Tables Show Details for All Gene Ontology Categories

    Supplementary Table 1: Association of Gene Ontology Categories with Decay Rate for HepG2 Experiments These tables show details for all Gene Ontology categories. Inferences for manual classification scheme shown at the bottom. Those categories used in Figure 1A are highlighted in bold. Standard Deviations are shown in parentheses. P-values less than 1E-20 are indicated with a "0". Rate r (hour^-1) Half-life < 2hr. Decay % GO Number Category Name Probe Sets Group Non-Group Distribution p-value In-Group Non-Group Representation p-value GO:0006350 transcription 1523 0.221 (0.009) 0.127 (0.002) FASTER 0 13.1 (0.4) 4.5 (0.1) OVER 0 GO:0006351 transcription, DNA-dependent 1498 0.220 (0.009) 0.127 (0.002) FASTER 0 13.0 (0.4) 4.5 (0.1) OVER 0 GO:0006355 regulation of transcription, DNA-dependent 1163 0.230 (0.011) 0.128 (0.002) FASTER 5.00E-21 14.2 (0.5) 4.6 (0.1) OVER 0 GO:0006366 transcription from Pol II promoter 845 0.225 (0.012) 0.130 (0.002) FASTER 1.88E-14 13.0 (0.5) 4.8 (0.1) OVER 0 GO:0006139 nucleobase, nucleoside, nucleotide and nucleic acid metabolism3004 0.173 (0.006) 0.127 (0.002) FASTER 1.28E-12 8.4 (0.2) 4.5 (0.1) OVER 0 GO:0006357 regulation of transcription from Pol II promoter 487 0.231 (0.016) 0.132 (0.002) FASTER 6.05E-10 13.5 (0.6) 4.9 (0.1) OVER 0 GO:0008283 cell proliferation 625 0.189 (0.014) 0.132 (0.002) FASTER 1.95E-05 10.1 (0.6) 5.0 (0.1) OVER 1.50E-20 GO:0006513 monoubiquitination 36 0.305 (0.049) 0.134 (0.002) FASTER 2.69E-04 25.4 (4.4) 5.1 (0.1) OVER 2.04E-06 GO:0007050 cell cycle arrest 57 0.311 (0.054) 0.133 (0.002)
  • Transient Activation of Meox1 Is an Early Component of the Gene

    Transient Activation of Meox1 Is an Early Component of the Gene

    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Access to Research and Communications Annals 1 Transient activation of Meox1 is an early component of the gene 2 regulatory network downstream of Hoxa2. 3 4 Pavel Kirilenko1, Guiyuan He1, Baljinder Mankoo2, Moises Mallo3, Richard Jones4, 5 5 and Nicoletta Bobola1,* 6 7 (1) School of Dentistry, Faculty of Medical and Human Sciences, University of 8 Manchester, Manchester, UK. 9 (2) Randall Division of Cell and Molecular Biophysics, King's College London, UK. 10 (3) Instituto Gulbenkian de Ciência, Oeiras, Portugal. 11 (4) Genetic Medicine, Manchester Academic Health Science Centre, Central 12 Manchester University Hospitals NHS Foundation Trust, Manchester, UK. 13 (5) Present address: Department of Biology, University of York, York, UK. 14 15 Running title: Hoxa2 activates Meox1 expression. 16 Keywords: Meox1, Hoxa2, homeodomain, development, mouse 17 *Words Count: Material and Methods: 344; Introduction, Results and Discussion: 18 3679 19 19 * Author for correspondence at: AV Hill Building The University of Manchester Manchester M13 9PT United Kingdom Phone: (+44) 161 3060642 E-mail: [email protected] 1 Abstract 2 Hox genes encode transcription factors that regulate morphogenesis in all animals 3 with bilateral symmetry. Although Hox genes have been extensively studied, their 4 molecular function is not clear in vertebrates, and only a limited number of genes 5 regulated by Hox transcription factors have been identified. Hoxa2 is required for 6 correct development of the second branchial arch, its major domain of expression. 7 We now show that Meox1 is genetically downstream from Hoxa2 and is a direct 8 target.
  • Supplemental Table S1 (A): Microarray Datasets Characteristics

    Supplemental Table S1 (A): Microarray Datasets Characteristics

    Supplemental table S1 (A): Microarray datasets characteristics Title Summary Samples Literature ref. GEO ref. Acquisition of granule Gene expression profiling of 27 (1) GSE 11859 neuron precursor identity cerebellar tumors generated and Hedgehog‐induced from various early and late medulloblastoma in mice. stage CNS progenitor cells Medulloblastomas derived Study of mouse 5 (2) GSE 7212 from Cxcr6 mutant mice medulloblastoma in response respond to treatment with to inhibitor of Smoothened a Smoothened inhibitor Expression profiles of Identification of distinct classes 10 (3) GSE 9299 mouse medulloblastoma of up‐regulated or down‐ 339 & 340 regulated genes during Hh dependent tumorigenesis Genetic alterations in Identification of differently 10 (4) GSE 6463 mouse medulloblastomas expressed genes among CGNPs 339 & and generation of tumors and CGNPs transfected with 340 from cerebellar granule retroviruses that express nmyc neuron precursors or cyclin‐d1 Patched heterozygous Analysis of granule cell 14 (5) GSE 2426 model of medulloblastoma precursors, pre‐neoplastic cells, GDS1110 and tumor cells 1. Schuller U, Heine VM, Mao J, Kho AT, Dillon AK, Han YG, et al. Acquisition of granule neuron precursor identity is a critical determinant of progenitor cell competence to form Shh‐induced medulloblastoma. Cancer Cell 2008;14:123‐134. 2. Sasai K, Romer JT, Kimura H, Eberhart DE, Rice DS, Curran T. Medulloblastomas derived from Cxcr6 mutant mice respond to treatment with a smoothened inhibitor. Cancer Res 2007;67:3871‐3877. 3. Mao J, Ligon KL, Rakhlin EY, Thayer SP, Bronson RT, Rowitch D, et al. A novel somatic mouse model to survey tumorigenic potential applied to the Hedgehog pathway. Cancer Res 2006;66:10171‐10178.
  • Supplementary Table S4. FGA Co-Expressed Gene List in LUAD

    Supplementary Table S4. FGA Co-Expressed Gene List in LUAD

    Supplementary Table S4. FGA co-expressed gene list in LUAD tumors Symbol R Locus Description FGG 0.919 4q28 fibrinogen gamma chain FGL1 0.635 8p22 fibrinogen-like 1 SLC7A2 0.536 8p22 solute carrier family 7 (cationic amino acid transporter, y+ system), member 2 DUSP4 0.521 8p12-p11 dual specificity phosphatase 4 HAL 0.51 12q22-q24.1histidine ammonia-lyase PDE4D 0.499 5q12 phosphodiesterase 4D, cAMP-specific FURIN 0.497 15q26.1 furin (paired basic amino acid cleaving enzyme) CPS1 0.49 2q35 carbamoyl-phosphate synthase 1, mitochondrial TESC 0.478 12q24.22 tescalcin INHA 0.465 2q35 inhibin, alpha S100P 0.461 4p16 S100 calcium binding protein P VPS37A 0.447 8p22 vacuolar protein sorting 37 homolog A (S. cerevisiae) SLC16A14 0.447 2q36.3 solute carrier family 16, member 14 PPARGC1A 0.443 4p15.1 peroxisome proliferator-activated receptor gamma, coactivator 1 alpha SIK1 0.435 21q22.3 salt-inducible kinase 1 IRS2 0.434 13q34 insulin receptor substrate 2 RND1 0.433 12q12 Rho family GTPase 1 HGD 0.433 3q13.33 homogentisate 1,2-dioxygenase PTP4A1 0.432 6q12 protein tyrosine phosphatase type IVA, member 1 C8orf4 0.428 8p11.2 chromosome 8 open reading frame 4 DDC 0.427 7p12.2 dopa decarboxylase (aromatic L-amino acid decarboxylase) TACC2 0.427 10q26 transforming, acidic coiled-coil containing protein 2 MUC13 0.422 3q21.2 mucin 13, cell surface associated C5 0.412 9q33-q34 complement component 5 NR4A2 0.412 2q22-q23 nuclear receptor subfamily 4, group A, member 2 EYS 0.411 6q12 eyes shut homolog (Drosophila) GPX2 0.406 14q24.1 glutathione peroxidase
  • The Oestrogen Receptor Alpha-Regulated Lncrna NEAT1 Is a Critical Modulator of Prostate Cancer

    The Oestrogen Receptor Alpha-Regulated Lncrna NEAT1 Is a Critical Modulator of Prostate Cancer

    ARTICLE Received 5 Dec 2013 | Accepted 26 Sep 2014 | Published 21 Nov 2014 DOI: 10.1038/ncomms6383 OPEN The oestrogen receptor alpha-regulated lncRNA NEAT1 is a critical modulator of prostate cancer Dimple Chakravarty1,2, Andrea Sboner1,2,3, Sujit S. Nair4, Eugenia Giannopoulou5,6, Ruohan Li7, Sven Hennig8, Juan Miguel Mosquera1,2, Jonathan Pauwels1, Kyung Park1, Myriam Kossai1,2, Theresa Y. MacDonald1, Jacqueline Fontugne1,2, Nicholas Erho9, Ismael A. Vergara9, Mercedeh Ghadessi9, Elai Davicioni9, Robert B. Jenkins10, Nallasivam Palanisamy11,12, Zhengming Chen13, Shinichi Nakagawa14, Tetsuro Hirose15, Neil H. Bander16, Himisha Beltran1,2, Archa H. Fox7, Olivier Elemento2,3 & Mark A. Rubin1,2 The androgen receptor (AR) plays a central role in establishing an oncogenic cascade that drives prostate cancer progression. Some prostate cancers escape androgen dependence and are often associated with an aggressive phenotype. The oestrogen receptor alpha (ERa)is expressed in prostate cancers, independent of AR status. However, the role of ERa remains elusive. Using a combination of chromatin immunoprecipitation (ChIP) and RNA-sequencing data, we identified an ERa-specific non-coding transcriptome signature. Among putatively ERa-regulated intergenic long non-coding RNAs (lncRNAs), we identified nuclear enriched abundant transcript 1 (NEAT1) as the most significantly overexpressed lncRNA in prostate cancer. Analysis of two large clinical cohorts also revealed that NEAT1 expression is asso- ciated with prostate cancer progression. Prostate cancer cells expressing high levels of NEAT1 were recalcitrant to androgen or AR antagonists. Finally, we provide evidence that NEAT1 drives oncogenic growth by altering the epigenetic landscape of target gene promoters to favour transcription. 1 Department of Pathology and Laboratory Medicine, Weill Medical College of Cornell University, 413 East 69th Street, Room 1402, New York, New York 10021, USA.
  • Identification of PBX1 Target Genes in Cancer Cells by Global Mapping of PBX1 Binding Sites

    Identification of PBX1 Target Genes in Cancer Cells by Global Mapping of PBX1 Binding Sites

    Identification of PBX1 Target Genes in Cancer Cells by Global Mapping of PBX1 Binding Sites Michelle M. Thiaville1., Alexander Stoeck1., Li Chen1,3, Ren-Chin Wu1, Luca Magnani4, Jessica Oidtman1, Ie-Ming Shih1,2, Mathieu Lupien4¤, Tian-Li Wang1,2* 1 Departments of Pathology and Oncology, Johns Hopkins Medical Institutions, Baltimore, Maryland, United States of America, 2 Department of Gynecology and Obstetrics, Johns Hopkins Medical Institutions, Baltimore, Maryland, United States of America, 3 Department of Electrical and Computer Engineering, Virginia Polytechnic Institute and State University, Arlington, Virginia, United States of America, 4 Institute of Quantitative Biomedical Sciences, Norris Cotton Cancer Center, Dartmouth Medical School, Lebanon, New Hampshire, United States of America Abstract PBX1 is a TALE homeodomain transcription factor involved in organogenesis and tumorigenesis. Although it has been shown that ovarian, breast, and melanoma cancer cells depend on PBX1 for cell growth and survival, the molecular mechanism of how PBX1 promotes tumorigenesis remains unclear. Here, we applied an integrated approach by overlapping PBX1 ChIP-chip targets with the PBX1-regulated transcriptome in ovarian cancer cells to identify genes whose transcription was directly regulated by PBX1. We further determined if PBX1 target genes identified in ovarian cancer cells were co-overexpressed with PBX1 in carcinoma tissues. By analyzing TCGA gene expression microarray datasets from ovarian serous carcinomas, we found co-upregulation of PBX1 and a significant number of its direct target genes. Among the PBX1 target genes, a homeodomain protein MEOX1 whose DNA binding motif was enriched in PBX1- immunoprecipicated DNA sequences was selected for functional analysis. We demonstrated that MEOX1 protein interacts with PBX1 protein and inhibition of MEOX1 yields a similar growth inhibitory phenotype as PBX1 suppression.
  • Novel and Highly Recurrent Chromosomal Alterations in Se´Zary Syndrome

    Novel and Highly Recurrent Chromosomal Alterations in Se´Zary Syndrome

    Research Article Novel and Highly Recurrent Chromosomal Alterations in Se´zary Syndrome Maarten H. Vermeer,1 Remco van Doorn,1 Remco Dijkman,1 Xin Mao,3 Sean Whittaker,3 Pieter C. van Voorst Vader,4 Marie-Jeanne P. Gerritsen,5 Marie-Louise Geerts,6 Sylke Gellrich,7 Ola So¨derberg,8 Karl-Johan Leuchowius,8 Ulf Landegren,8 Jacoba J. Out-Luiting,1 Jeroen Knijnenburg,2 Marije IJszenga,2 Karoly Szuhai,2 Rein Willemze,1 and Cornelis P. Tensen1 Departments of 1Dermatology and 2Molecular Cell Biology, Leiden University Medical Center, Leiden, the Netherlands; 3Department of Dermatology, St Thomas’ Hospital, King’s College, London, United Kingdom; 4Department of Dermatology, University Medical Center Groningen, Groningen, the Netherlands; 5Department of Dermatology, Radboud University Nijmegen Medical Center, Nijmegen, the Netherlands; 6Department of Dermatology, Gent University Hospital, Gent, Belgium; 7Department of Dermatology, Charite, Berlin, Germany; and 8Department of Genetics and Pathology, Rudbeck Laboratory, University of Uppsala, Uppsala, Sweden Abstract Introduction This study was designed to identify highly recurrent genetic Se´zary syndrome (Sz) is an aggressive type of cutaneous T-cell alterations typical of Se´zary syndrome (Sz), an aggressive lymphoma/leukemia of skin-homing, CD4+ memory T cells and is cutaneous T-cell lymphoma/leukemia, possibly revealing characterized by erythroderma, generalized lymphadenopathy, and pathogenetic mechanisms and novel therapeutic targets. the presence of neoplastic T cells (Se´zary cells) in the skin, lymph High-resolution array-based comparative genomic hybridiza- nodes, and peripheral blood (1). Sz has a poor prognosis, with a tion was done on malignant T cells from 20 patients. disease-specific 5-year survival of f24% (1).